AU2019340475B2 - Methods for modulating regulatory T cells and inhibiting tumor growth - Google Patents

Methods for modulating regulatory T cells and inhibiting tumor growth Download PDF

Info

Publication number
AU2019340475B2
AU2019340475B2 AU2019340475A AU2019340475A AU2019340475B2 AU 2019340475 B2 AU2019340475 B2 AU 2019340475B2 AU 2019340475 A AU2019340475 A AU 2019340475A AU 2019340475 A AU2019340475 A AU 2019340475A AU 2019340475 B2 AU2019340475 B2 AU 2019340475B2
Authority
AU
Australia
Prior art keywords
cancer
treg
antibody
intratumoral
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019340475A
Other languages
English (en)
Other versions
AU2019340475A1 (en
Inventor
Ping-Chih HO
Haiping WANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Lausanne
Original Assignee
Universite de Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Lausanne filed Critical Universite de Lausanne
Publication of AU2019340475A1 publication Critical patent/AU2019340475A1/en
Application granted granted Critical
Publication of AU2019340475B2 publication Critical patent/AU2019340475B2/en
Priority to AU2025205589A priority Critical patent/AU2025205589A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019340475A 2018-09-14 2019-09-13 Methods for modulating regulatory T cells and inhibiting tumor growth Active AU2019340475B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025205589A AU2025205589A1 (en) 2018-09-14 2025-07-17 Methods for modulating regulatory T cells and inhibiting tumor growth

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862731351P 2018-09-14 2018-09-14
US62/731,351 2018-09-14
PCT/IB2019/057745 WO2020053833A1 (en) 2018-09-14 2019-09-13 Methods for modulating regulatory t cells and inhibiting tumor growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025205589A Division AU2025205589A1 (en) 2018-09-14 2025-07-17 Methods for modulating regulatory T cells and inhibiting tumor growth

Publications (2)

Publication Number Publication Date
AU2019340475A1 AU2019340475A1 (en) 2021-03-11
AU2019340475B2 true AU2019340475B2 (en) 2025-04-17

Family

ID=68393033

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019340475A Active AU2019340475B2 (en) 2018-09-14 2019-09-13 Methods for modulating regulatory T cells and inhibiting tumor growth
AU2025205589A Pending AU2025205589A1 (en) 2018-09-14 2025-07-17 Methods for modulating regulatory T cells and inhibiting tumor growth

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025205589A Pending AU2025205589A1 (en) 2018-09-14 2025-07-17 Methods for modulating regulatory T cells and inhibiting tumor growth

Country Status (7)

Country Link
US (1) US20220049010A1 (https=)
EP (1) EP3849666B1 (https=)
JP (2) JP2022500448A (https=)
CN (2) CN121534175A (https=)
AU (2) AU2019340475B2 (https=)
CA (1) CA3109563A1 (https=)
WO (1) WO2020053833A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2990885A1 (en) 2015-06-30 2017-01-05 Sanford-Burnham Medical Research Institute Btla fusion protein agonists and uses thereof
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用
WO2021152548A1 (en) * 2020-01-30 2021-08-05 Benitah Salvador Aznar Combination therapy for treatment of cancer and cancer metastasis
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017055411A1 (en) * 2015-09-29 2017-04-06 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Targeting metastasis stem cells through a fatty acid receptor (cd36)
WO2019158581A1 (en) * 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with cd36 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO20004844L (no) * 2000-09-27 2002-05-10 Thia Medica As Fettsyre analoger for behandling av proliferative hudsykdommer
KR20070022197A (ko) * 2003-11-05 2007-02-26 팔링겐, 인코포레이티드 Ｃｄｉｍ 결합 항체의 증강된 ｂ 세포 세포독성
JP2008521814A (ja) * 2004-11-24 2008-06-26 シェーリング コーポレイション Ｄａｐ−１０およびその使用
JP2012149004A (ja) * 2011-01-18 2012-08-09 Theravalues Corp 核内受容体の賦活剤
CA2988119A1 (en) * 2015-06-03 2016-12-08 Dana-Farber Cancer Institute, Inc. Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
WO2018029336A1 (en) * 2016-08-12 2018-02-15 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017055411A1 (en) * 2015-09-29 2017-04-06 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Targeting metastasis stem cells through a fatty acid receptor (cd36)
WO2019158581A1 (en) * 2018-02-13 2019-08-22 Vib Vzw Targeting minimal residual disease in cancer with cd36 antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AL-KHAMI AMIR A. et al, ONCOIMMUNOLOGY, vol. 6, no. 10, 3 October 2017 (2017-10-03), pages e1344804, XP093015368, DOI: 10.1080/2162402X.2017.1344804 *
DENNIS LINDAU et al, CANCER RESEARCH, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 138, no. 2, 16 January 2013 (2013-01-16), GB , pages 105 - 115, XP071276372, ISSN: 0019-2805, DOI: 10.1111/imm.12036 *
YANG P. ET AL.: "Dietary oleic acid-induced CD36 promotes cervical cancer cell growth and metastasis via up-regulation Src/ERK pathway.", CANCER LETTERS, vol. 438, 11 September 2018 (2018-09-11), pages 76 - 85, XP002796200 *

Also Published As

Publication number Publication date
AU2019340475A1 (en) 2021-03-11
JP2024153816A (ja) 2024-10-29
CN112703039A (zh) 2021-04-23
EP3849666A1 (en) 2021-07-21
WO2020053833A1 (en) 2020-03-19
CA3109563A1 (en) 2020-03-19
EP3849666B1 (en) 2026-04-15
US20220049010A1 (en) 2022-02-17
CN121534175A (zh) 2026-02-17
AU2025205589A1 (en) 2025-08-07
JP2022500448A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
AU2025205589A1 (en) Methods for modulating regulatory T cells and inhibiting tumor growth
US20190269744A1 (en) Biomarkers and combination therapies using oncolytic virus and immunomodulation
KR102229873B1 (ko) 면역 반응의 향상
US11207393B2 (en) Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
US20240262909A1 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
KR20210035805A (ko) 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
WO2020086440A1 (en) Immunomodulatory compounds
JP2022512973A (ja) 腫瘍微小環境の組成を測定するための方法及び組成物
Zhang et al. P2RX1-blocked neutrophils induce CD8+ T cell dysfunction and affect the immune escape of gastric cancer cells
EP3760197B1 (en) Transport protein inhibitor for reducing expression of pd-1
HK40045698A (en) Methods for modulating regulatory t cells and inhibiting tumor growth
HK40018875A (en) Biomarkers and combination therapies using oncolytic virus and immunomodulation
WO2020146772A1 (en) Neuritin regulation of t cell anergy and t regulatory cell function
HK1204577B (en) Biomarkers and combination therapies using oncolytic virus and immunomodulation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)